These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31235241)

  • 21. Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: Analysis and management of complications in upper abdominal surgery.
    Benedetti Panici P; Di Donato V; Fischetti M; Casorelli A; Perniola G; Musella A; Marchetti C; Palaia I; Berloco P; Muzii L
    Gynecol Oncol; 2015 Jun; 137(3):406-11. PubMed ID: 25824857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postoperative complications in women with ovarian cancer stratified by cytoreductive surgery outcome.
    Polan RM; Slota JM; Barber EL
    J Surg Oncol; 2023 Oct; 128(5):891-901. PubMed ID: 37382209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Outcome After Completion Surgery in Patients With Ovarian Cancer: The Charite Experience.
    Babayeva A; Braicu EI; Grabowski JP; Gasimli K; Richter R; Muallem MZ; Sehouli J
    Int J Gynecol Cancer; 2018 Oct; 28(8):1491-1497. PubMed ID: 30095708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Total retroperitoneal en bloc resection of multivisceral-peritoneal packet (TROMP operation): a novel surgical technique for advanced ovarian cancer.
    Muallem MZ; Sehouli J; Miranda A; Richter R; Muallem J
    Int J Gynecol Cancer; 2020 May; 30(5):648-653. PubMed ID: 32221020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic role of mesenteric lymph nodes involvement in patients undergoing posterior pelvic exenteration during radical or supra-radical surgery for advanced ovarian cancer.
    Berretta R; Capozzi VA; Sozzi G; Volpi L; Ceni V; Melpignano M; Giordano G; Marchesi F; Monica M; Di Serio M; Riccò M; Ceccaroni M
    Arch Gynecol Obstet; 2018 Apr; 297(4):997-1004. PubMed ID: 29380107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maximal surgical effort increases the risk of postoperative complications in the treatment of advanced ovarian cancer.
    Kuusela K; Norppa N; Auranen A; Saarelainen S
    Eur J Surg Oncol; 2022 Dec; 48(12):2525-2530. PubMed ID: 35717320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival.
    Ross MS; Burriss ME; Winger DG; Edwards RP; Courtney-Brooks M; Boisen MM
    Gynecol Oncol; 2018 Aug; 150(2):306-310. PubMed ID: 29929924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perioperative fluid balance and major postoperative complications in surgery for advanced epithelial ovarian cancer.
    Hasselgren E; Hertzberg D; Camderman T; Björne H; Salehi S
    Gynecol Oncol; 2021 May; 161(2):402-407. PubMed ID: 33715894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unanticipated 30-day readmission following rectosigmoid resection at the time of cytoreductive surgery in patients with advanced stage ovarian cancer.
    Sanders BE; Saharti S; Laus K; Bristow RE; Eskander RN
    J Obstet Gynaecol; 2021 Aug; 41(6):956-961. PubMed ID: 33228421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical observation of partial pancreatectomy as part of primary cytoreductive surgery in advanced epithelial ovarian cancer].
    Xiang LB; Tu YX; He TC; Pei X; Shen XX; Yang WT; Wu XH; Yang HJ
    Zhonghua Fu Chan Ke Za Zhi; 2016 May; 51(5):361-5. PubMed ID: 27256444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Total rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian cancer.
    Plotti F; Montera R; Aloisi A; Scaletta G; Capriglione S; Luvero D; De Cicco Nardone C; Basile S; Benedetti Panici P; Angioli R
    Eur J Surg Oncol; 2016 Mar; 42(3):383-90. PubMed ID: 26725211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
    Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
    Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of venous thromboembolism after standard treatment in patients with epithelial ovarian cancer in Korea.
    Shin W; Lee S; Lim MC; Jung J; Kim HJ; Cho H
    Cancer Med; 2021 Mar; 10(6):2045-2053. PubMed ID: 33638309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pre-operative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer.
    Chesnais M; Lecuru F; Mimouni M; Ngo C; Fauconnier A; Huchon C
    PLoS One; 2017; 12(11):e0187245. PubMed ID: 29117194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is the interval from surgery to ileostomy closure a risk factor for low anterior resection syndrome?
    Jiménez-Rodríguez RM; Segura-Sampedro JJ; Rivero-Belenchón I; Díaz Pavón JM; García Cabrera AM; Vazquez Monchul JM; Padillo J; de la Portilla F
    Colorectal Dis; 2017 May; 19(5):485-490. PubMed ID: 27634544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of preoperative nutritional status using BIA-derived phase angle (PhA) in patients with advanced ovarian cancer: Correlation with the extent of cytoreduction and complications.
    Uccella S; Mele MC; Quagliozzi L; Rinninella E; Nero C; Cappuccio S; Cintoni M; Gasbarrini A; Scambia G; Fagotti A
    Gynecol Oncol; 2018 May; 149(2):263-269. PubMed ID: 29550182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Value of the Age-Adjusted Charlson Comorbidity Index (ACCI) on Short- and Long-Term Outcome in Patients with Advanced Primary Epithelial Ovarian Cancer.
    Kahl A; du Bois A; Harter P; Prader S; Schneider S; Heitz F; Traut A; Alesina PF; Meier B; Walz M; Brueckner A; Groeben HT; Brunkhorst V; Heikaus S; Ataseven B
    Ann Surg Oncol; 2017 Nov; 24(12):3692-3699. PubMed ID: 28871563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive Factors for Surgical Morbidities and Adjuvant Chemotherapy Delay for Advanced Ovarian Cancer Patients Treated by Primary Debulking Surgery or Interval Debulking Surgery.
    Castro BGR; Dos Reis R; Cintra GF; Sousa MMA; Vieira MA; Andrade CEMDC
    Int J Gynecol Cancer; 2018 Oct; 28(8):1520-1528. PubMed ID: 30036229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of primary debulking in advanced ovarian cancer patients.
    Vlad C; Kubelac P; Alexandru I; Achimas-Cadariu P
    J BUON; 2016; 21(5):1320. PubMed ID: 27837639
    [No Abstract]   [Full Text] [Related]  

  • 40. A collaborative surgical approach to upper and lower abdominal cytoreductive surgery in ovarian cancer.
    Eng OS; Raoof M; Blakely AM; Yu X; Lee SJ; Han ES; Wakabayashi MT; Yuh B; Lee B; Dellinger TH
    J Surg Oncol; 2018 Jul; 118(1):121-126. PubMed ID: 29878375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.